AstraZeneca closes India R&D shop

AstraZeneca is laying off 168 pharmaceutical employees at the Avishkar R&D site in Bangalore, India. The company said in a statement that the move is in line with its shift to focus on three core areas—oncology; cardiovascular and metabolic; and respiratory, inflammation and autoimmunity.

The Avishkar operation was focused on conditions including TB, malaria and neglected tropical diseases. AstraZeneca will continue to develop Phase-II TB medication AZD5847. The company said it will continue to make its compound library available to open-innovation partnerships.

You must be a registered member of MMM to post a comment.
 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.